JP4975922B2 - １つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療 - Google Patents

１つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療 Download PDF

Info

Publication number
JP4975922B2
JP4975922B2 JP2001523027A JP2001523027A JP4975922B2 JP 4975922 B2 JP4975922 B2 JP 4975922B2 JP 2001523027 A JP2001523027 A JP 2001523027A JP 2001523027 A JP2001523027 A JP 2001523027A JP 4975922 B2 JP4975922 B2 JP 4975922B2
Authority
JP
Japan
Prior art keywords
antibody
integrin
vla
fragment
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001523027A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003509380A5 (cg-RX-API-DMAC7.html
JP2003509380A (ja
Inventor
アンドリュー アレン，
チャールズ パシィー，
ロイ ロブ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Inc
Biogen Idec Inc
Biogen Idec MA Inc
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Biogen Idec Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Biogen Inc
Publication of JP2003509380A publication Critical patent/JP2003509380A/ja
Publication of JP2003509380A5 publication Critical patent/JP2003509380A5/ja
Application granted granted Critical
Publication of JP4975922B2 publication Critical patent/JP4975922B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2001523027A 1999-09-14 2000-09-14 １つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療 Expired - Fee Related JP4975922B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15382699P 1999-09-14 1999-09-14
US60/153,826 1999-09-14
PCT/US2000/025140 WO2001019396A1 (en) 1999-09-14 2000-09-14 Therapies for chronic renal failure using one or more integrin antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011059947A Division JP5463316B2 (ja) 1999-09-14 2011-03-17 １つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療

Publications (3)

Publication Number Publication Date
JP2003509380A JP2003509380A (ja) 2003-03-11
JP2003509380A5 JP2003509380A5 (cg-RX-API-DMAC7.html) 2007-11-08
JP4975922B2 true JP4975922B2 (ja) 2012-07-11

Family

ID=22548902

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2001523027A Expired - Fee Related JP4975922B2 (ja) 1999-09-14 2000-09-14 １つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療
JP2011059947A Expired - Fee Related JP5463316B2 (ja) 1999-09-14 2011-03-17 １つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療
JP2013053308A Withdrawn JP2013116916A (ja) 1999-09-14 2013-03-15 １つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2011059947A Expired - Fee Related JP5463316B2 (ja) 1999-09-14 2011-03-17 １つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療
JP2013053308A Withdrawn JP2013116916A (ja) 1999-09-14 2013-03-15 １つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療

Country Status (13)

Country Link
US (3) US20030007969A1 (cg-RX-API-DMAC7.html)
EP (1) EP1214091B1 (cg-RX-API-DMAC7.html)
JP (3) JP4975922B2 (cg-RX-API-DMAC7.html)
AT (1) ATE325623T1 (cg-RX-API-DMAC7.html)
AU (1) AU783266B2 (cg-RX-API-DMAC7.html)
CA (1) CA2384948C (cg-RX-API-DMAC7.html)
CY (1) CY1105117T1 (cg-RX-API-DMAC7.html)
DE (1) DE60027907T2 (cg-RX-API-DMAC7.html)
DK (1) DK1214091T3 (cg-RX-API-DMAC7.html)
ES (1) ES2263485T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ517781A (cg-RX-API-DMAC7.html)
PT (1) PT1214091E (cg-RX-API-DMAC7.html)
WO (1) WO2001019396A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1506359A (zh) 2002-12-05 2004-06-23 �й�ҽѧ��ѧԺҩ���о��� 新的香豆素酰胺衍生物及其制法和其药物组合物与用途
US7767219B2 (en) 2003-01-31 2010-08-03 Boston Scientific Scimed, Inc. Localized drug delivery using drug-loaded nanocapsules
US20070048383A1 (en) * 2005-08-25 2007-03-01 Helmus Michael N Self-assembled endovascular structures
DE102009000854A1 (de) * 2009-02-13 2010-08-19 Ernst-Moritz-Arndt-Universität Greifswald Osteopontin-Rezeptor-Liganden zur Behandlung des chronischen Nierenversagens
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004247A1 (en) * 1996-07-25 1998-02-05 Biogen, Inc. Cell adhesion inhibitors
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111657A (en) * 1977-01-21 1978-09-05 American Monitor Corporation Creatinine assay and reagent system
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US6307025B1 (en) * 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
USRE40811E1 (en) * 1992-11-13 2009-06-30 Board Of Regents Of The University Of Washington Peripheralization of hematopoietic stem cells
SG44845A1 (en) * 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
WO1994017828A2 (en) * 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
ES2285841T3 (es) * 1998-05-22 2007-11-16 Boys Town National Research Hospital Uso de inhibidores del receptor de integrina alfa1beta1 e inhibidores de tgf-beta1 en el tratamiento de la enfermedad renal.
US7618630B2 (en) * 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
ES2319831T3 (es) * 1998-09-14 2009-05-12 Board Of Regents, The University Of Texas System Metodos de tratamiento de mieloma multiple y resorcion osea inducida por mieloma usando antagonistas de la union receptor/integrina.
US6245885B1 (en) * 1998-10-05 2001-06-12 Mcgill University Bax-mediated apoptosis modulating reagents and methods
AU783110B2 (en) * 1999-12-16 2005-09-22 Biogen Ma Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
WO1998004247A1 (en) * 1996-07-25 1998-02-05 Biogen, Inc. Cell adhesion inhibitors

Also Published As

Publication number Publication date
DE60027907D1 (de) 2006-06-14
DE60027907T2 (de) 2007-01-04
US20110305686A1 (en) 2011-12-15
ATE325623T1 (de) 2006-06-15
JP2013116916A (ja) 2013-06-13
EP1214091A1 (en) 2002-06-19
JP2011116791A (ja) 2011-06-16
ES2263485T3 (es) 2006-12-16
CA2384948A1 (en) 2001-03-22
CA2384948C (en) 2013-07-16
AU783266B2 (en) 2005-10-06
NZ517781A (en) 2004-01-30
PT1214091E (pt) 2006-09-29
US20140234299A1 (en) 2014-08-21
EP1214091B1 (en) 2006-05-10
JP2003509380A (ja) 2003-03-11
WO2001019396A1 (en) 2001-03-22
US20030007969A1 (en) 2003-01-09
AU7379200A (en) 2001-04-17
CY1105117T1 (el) 2010-03-03
DK1214091T3 (da) 2006-08-28
JP5463316B2 (ja) 2014-04-09

Similar Documents

Publication Publication Date Title
JP5519612B2 (ja) 中枢神経系の虚血性損傷または出血性損傷を、抗α４インテグリンアンタゴニストを用いて処置する方法
US20150056205A1 (en) Steroid sparing agents and methods of using same
KR100628818B1 (ko) 인테그린 길항제를 사용하여 다발성 골수종 및 골수종에의한 골흡수를 치료하는 방법
JP2014065747A (ja) インテグリンα−４サブユニットのアンタゴニストを使用する線維症の処置のための方法
JP5463316B2 (ja) １つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療
US20100183599A1 (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
EP1700606A1 (en) Therapies for chronic renal failure using one or more integrin antagonists
HK1094948A (en) Therapies for chronic renal failure using one or more integrin antagonists
HK1092714A (en) Method for treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
EP1666063A2 (en) Method for treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
HK1158085A (en) Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070912

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100917

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101222

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110722

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110729

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110824

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20111025

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120319

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120412

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150420

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees